Introduction {#s1}
============

Non-Hodgkin lymphoma (NHL), a heterogeneous group of lymphoid malignancies [@pone.0105027-Guerard1], [@pone.0105027-Shankland1], is the eleventh most common cause of death from cancer in humans worldwide, estimated to be responsible for approximately 192,000 deaths in 2008 alone [@pone.0105027-UK1]. Despite advances in therapy in recent years, five-year survival rates are as low as 25% for the more aggressive subtypes of NHL [@pone.0105027-UK1]. There is thus an urgent need to develop novel, targeted therapies for this group of diseases, driven by advances in our understanding of their pathogenesis and specific prognosis. Current rodent models of lymphoma are far from predictive of the natural course of the human disease, relying either on the subcutaneous implantation of xenogeneic lymphoma cells into immune-compromised mice, or on genetic manipulations that artificially increase the likelihood of lymphoma in a monogenic fashion [@pone.0105027-OConnor1]. Key to advancing the field will be the development of natural, polygenic animal models of NHL, allowing the further interrogation of molecular and cellular pathogenesis, as well as trials of novel anti-cancer agents. The dog has gained traction in recent years as a model for a number of human diseases, including various malignancies [@pone.0105027-Head1]--[@pone.0105027-Tsai1]. Its spontaneous development of mesenchymal, epithelial and round cell tumors, relatively short lifespan, and cohabitation of our environment, as well as the availability of advanced diagnostic and therapeutic modalities that are similar to those available in human oncology clinics, all make this species attractive as a model for cancer research [@pone.0105027-Ranieri1], [@pone.0105027-Gordon1], [@pone.0105027-Paoloni1]. Furthermore, the most prevalent subtype of canine lymphoma, diffuse large (DL) BCL, mirrors the most common form of NHL [@pone.0105027-Marconato1], and various studies suggest that the molecular pathogenesis of DLBCL in the two species is fundamentally similar [@pone.0105027-Frantz1]--[@pone.0105027-Su1].

One of the key pathogenic determinants in oncogenesis is the cancer microenvironment [@pone.0105027-Schiavoni1]--[@pone.0105027-Fridman1]. Interactions with stromal and immune cells and extracellular matrix components conspire to inhibit anti-neoplastic immune responses, allowing the cancer to grow and metastasize. Central among such cellular interactions are those occurring with Tregs, of which the thymic subset is generally identified by its expression of the Forkhead box transcription factor FOXP3 in addition to the classical markers CD4 and CD25^high^ [@pone.0105027-Garden1]. While the negative prognostic impact of FOXP3^+^ Tregs in various solid tumors of both mesenchymal and epithelial origin has been well documented [@pone.0105027-Gallimore1], [@pone.0105027-Oleinika1], these cells have also been associated with a favorable outcome in certain solid tumors [@pone.0105027-Dobrzanski1], [@pone.0105027-deLeeuw1] and their role in the pathogenesis of lymphoid malignancies is much less clear [@pone.0105027-Lindqvist1]. Some papers suggest that intra-tumoral Tregs predict a negative outcome in human lymphoma [@pone.0105027-Marshall1]--[@pone.0105027-Schreck1], while others suggest that they may have a beneficial effect [@pone.0105027-Alvaro1]--[@pone.0105027-Dehghani1]; yet others propose that they have neither a positive nor a negative prognostic impact [@pone.0105027-Koch1]. The situation is further complicated by the presence of more than one subset of Treg -- including both thymic and peripheral IL-10-secreting (Tr1) phenotypes -- and interactions with other cells with suppressive properties, including myeloid-derived suppressor cells, natural killer T (NKT) cells and tolerogenic dendritic cells [@pone.0105027-Lindau1]--[@pone.0105027-Adeegbe1].

While a number of recent studies have added weight to the suggestion that lymphoma in the dog closely resembles human NHL [@pone.0105027-Frantz1]--[@pone.0105027-Su1], very little is known about the role of Tregs in canine BCL. We and others have recently characterised FOXP3^+^ Tregs in the dog [@pone.0105027-Pinheiro1], demonstrating that they have similar properties to those of human Tregs; we were thus optimally poised to interrogate their role in various canine diseases, including lymphoma. The aim of the present study was therefore to document the presence of FOXP3^+^ Tregs in the resident T cell population of affected lymph nodes of dogs with B cell lymphoma (BCL) and to test the hypothesis that intra-tumoral CD4^+^FOXP3^+^ Tregs have a negative impact on treatment outcome, making comparisons with dogs with T cell lymphoma (TCL), non-neoplastic causes of lymphadenomegaly, and metastatic mast cell tumors (MCTs). Our goal was to advance our understanding of the pathogenesis of canine BCL, thus further validating this spontaneous, naturally occurring disease as a large animal model of NHL in which to study the role of immunoregulatory pathways.

Materials and Methods {#s2}
=====================

Case accession {#s2a}
--------------

Dogs were recruited to this study from four different veterinary practices, three located in the UK and one in Sweden. Complete clinical histories were obtained from every dog. Diagnostic investigations appropriate to the presenting complaints were undertaken in all dogs, including cytological and, or histopathological review of enlarged lymph nodes by a board-certified veterinary pathologist. Standard clinical staging was undertaken by means of thoracic radiographs or computed tomography; abdominal ultrasound examination; fine needle aspirates (FNAs) of the liver and spleen when sonographic lesions of these organs were identified; and bone marrow aspirates when prompted by peripheral cytopenias. Stages IV and V were thus assigned with the caveat that aspirates of the liver, spleen and bone marrow were not undertaken in every dog. Study samples comprised blood collected by venepuncture of a peripheral vein into EDTA and serum gel tubes, and three to four fine needle aspirates (FNAs) of a representative, enlarged lymph node deposited into neat fetal bovine serum (PAA Laboratories Ltd, Yeovil, UK) for flow cytometry. Staining of cells for flow cytometry was performed within 48 hours of sample collection, followed by acquisition of the fixed cells within a further 72 hours. (Pilot studies had established that the immunophenotype of samples remained stable up to 48 hours after sample collection.) Serum was harvested within two hours of sample collection and was stored at a temperature of −20°C until analysis.

Twenty-two of the dogs recruited were diagnosed with BCL, whilst the remaining cases were recruited to three different control groups. The first comprised 14 dogs with TCL; the second comprised 14 dogs with reactive hyperplasia (RH) associated with cutaneous inflammation/dermatitis, immune-mediated disease, distant neoplasia (i.e. non-draining lymph nodes were sampled) or systemic infection; while the third comprised six dogs with metastatic MCTs, the samples in these cases having been collected from draining lymph nodes. Flow cytometric analyses of peripheral blood were undertaken in these dogs and a group of 25 healthy control (HC) dogs, which also contributed serum samples. (C-reactive protein and cytokine assays, reported elsewhere, were undertaken on all of the serum samples.) For ethical and legal reasons, lymph node samples could not be obtained from HC dogs. All patient samples were collected by licensed veterinarians in routine diagnostic fashion following written informed consent and all study protocols were approved by the Royal Veterinary College Ethics and Welfare Committee (Permit Number: URN-20101005). None of the dogs suffered any adverse consequences of sample procurement.

Cytomorphological classification {#s2b}
--------------------------------

When available, slides of diagnostic specimens were retrieved from the receiving diagnostic laboratories for review by a board-certified clinical pathologist involved in the study (BS) for cytomorphological classification. Cytological features that were recorded in the study are presented in [Table S1](#pone.0105027.s003){ref-type="supplementary-material"}. Based on these observations and the immunophenotype of the lymphoma, the most likely subtype was deduced -- for example, DLBCL -- though histopathological review would have been required to confirm such tissue diagnoses.

Flow cytometry {#s2c}
--------------

A panel of canine-specific or cross-reactive fluorochrome-conjugated monoclonal antibodies (mAbs) against both extra- and intra-cellular antigens was applied ([Table 1](#pone-0105027-t001){ref-type="table"}). The manufacturer\'s protocol for FOXP3 staining was applied. Briefly, lymphocytes were washed and stained with mAbs for 20 minutes on ice. Lymphocytes were then washed and incubated overnight in a 1∶4 (concentrate:diluent) fixation/permeabilization solution. Following incubation, the lymphocytes were washed twice and then stained with mAbs against intracellular antigens for 30 minutes on ice. All incubations were carried out in the dark. Upon completion, lymphocytes were washed twice and re-suspended in 200 µl phosphate buffered saline (PBS) solution. Isotype control antibodies were used to define gates in all experiments. Three-colour staining was used throughout the study, T cells identified in a panel comprising mAbs against CD5 and FOXP3 with CD4, CD8 or Helios. Data were acquired using a FACS Canto II flow cytometer (BD Biosciences) and were analyzed using Flowjo (Tree Star Inc) software.

10.1371/journal.pone.0105027.t001

###### Staining antibodies, isotype controls and fluorochromes.

![](pone.0105027.t001){#pone-0105027-t001-1}

  Antigen      Clone           Isotype          Fluorochrome      Supplier
  --------- ----------- ---------------------- -------------- -----------------
  CD5        YKIX322.3        Rat IgG2a           FITC/PE      AbD Serotec, UK
  CD4        YKIX302.9        Rat IgG2a           FITC/PE      AbD Serotec, UK
  CD8        YCATE55.9         Rat IgG1           FITC/PE      AbD Serotec, UK
  CD79b       AT107-2          Rat IgG1             FITC       AbD Serotec, UK
  CD21        CA2.1D6         Mouse IgG1             PE        AbD Serotec, UK
  CD34          1H6           Mouse IgG1             PE        AbD Serotec, UK
  FOXP3       FJK-16s         Rat IgG2a             APC        eBioscience, UK
  Helios       22F6      Armenian hamster IgG        PE         Biolegend, UK

[Abbreviations]{.ul}: FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin.

Immunophenotypic determination {#s2d}
------------------------------

A threshold of 60% marker expression was used to classify patient samples as being of either a B or T cell phenotype, adopting a previously validated diagnostic protocol [@pone.0105027-Wilkerson1]. This threshold was applied to the 30% of largest events following removal of dead cells and debris by appropriate gating, as determined by forward and side scatter characteristics ([Figure 1](#pone-0105027-g001){ref-type="fig"}). Where at least 60% of cells expressed CD21 or CD79b, a classification of BCL was made. Conversely, when at least 60% of cells expressed CD5, CD4 or CD8 a classification of TCL was made. To further interrogate the composition of cell populations in FNAs, an 'All' gate was applied, which again excluded dead events. Non-neoplastic and neoplastic populations of cells within the BCL FNAs were then evaluated on the basis of CD5 expression, which was limited to the resident (non-neoplastic) T cells in the majority of such cases. An equivalent strategy was applied to both the RH and MCT groups; however, TCL samples were excluded from this analysis owing to CD5 expression by both neoplastic and non-neoplastic cells, which precluded distinction of the two populations within the aspirated cells. In all cases, the expression of CD34 in peripheral blood was negligible, ruling out leukemia.

![Gating strategies used to interrogate the neoplastic and non-neoplastic cell populations.\
Following exclusion of dead cells and debris, two different gating strategies were employed to evaluate the cells isolated from lymph node aspirates. For the purposes of generating an immunophenotyping profile, an upper 30% gate was applied to identify the population of largest events, enriched in neoplastic cells. The immunophenotype was then determined using a 60% expression threshold within this population. For the purposes of evaluating frequencies of T cells within fine needle aspirates of B cell lymphoma (BCL), reactive hyperplasia (RH) and mast cell tumour (MCT) cases, an 'All' gate was applied and then the populations subsequently delineated by means of CD5 expression. Non-neoplastic cells were identified as CD5^+^ and neoplastic populations CD5^−^ in the context of BCL; TCL cases were excluded from such comparisons on account of their CD5 expression by both neoplastic and non-neoplastic cells.](pone.0105027.g001){#pone-0105027-g001}

Clinical definitions and statistical analysis {#s2e}
---------------------------------------------

The following outcome metrics were derived from patient records and communications with the clinicians involved in this study: time to remission (TTR), progression-free survival (PFS) and overall survival (OS). These parameters were determined following assessment of the response to therapy using Veterinary Cooperative Oncology Group-approved definitions of complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) applied to peripheral lymph nodes measured by the attending clinicians [@pone.0105027-Vail1].

Comparisons between two groups of continuous data were undertaken using Mann-Whitney U tests and for three or more groups using Kruskal-Wallis tests. Summary data are presented in the text in the following format: median, range \[lowest to highest value\], number of cases or experimental repeats (n); p value. Summary data are presented in the form of box plots, in which the boxes show the respective 25^th^ and 75^th^ percentiles, the horizontal lines median values, and the whiskers, the lowest and highest data points still within 1.5 times the interquartile range of the respective lower and upper quartiles. Dots represent the data from individual dogs. Red symbols correspond to data from dogs 'pre-treated' with corticosteroids or any chemotherapeutic drug within three weeks of sampling. In the case of RH cases, square symbols represent data from dogs with *dermatitis*; diamonds represent data from dogs with *distant neoplasia*; triangles represent data from dogs with *immune-mediated disease*; and inverted triangles represent data from dogs with *systemic infection*.

Survival analysis of the dogs with lymphoma was performed using Cox\'s proportional hazards regression and presented in the form of Kaplan-Meier curves. Continuous variables were categorised to produce the Kaplan-Meier curves using the median value as a threshold. Both univariable and multivariable analyses were undertaken. Criteria for inclusion of variables into the multivariable model included significance at the level of univariable analysis, lack of overlap of the respective survival curves, and constancy of the risk (hazard) with time. Only the BCL cases were analyzed as a separate group for the prognostic impact of phenotypic variables; there were too few TCL cases to make survival analysis of phenotypic variables of this group meaningful. Dogs that failed to go into complete remission were censored for TTR analysis; those that did not show progression, including death, at the last known follow-up time point were censored for PFS analysis; and those that were still alive at the last known follow-up time point were censored for OS analysis. Rescue therapy was not a criterion for censorship in the OS analysis.

Results {#s3}
=======

Clinical and immunophenotypic details of cases and controls {#s3a}
-----------------------------------------------------------

A total of 22 BCL, 14 TCL, 14 RH, six MCT and 25 HC dogs were recruited into the study. A summary of the signalment and clinical details of the BCL, TCL, RH, MCT and HC cases is presented in [Table 2](#pone-0105027-t002){ref-type="table"}; further details are presented in [Tables S2](#pone.0105027.s004){ref-type="supplementary-material"} to [S5](#pone.0105027.s007){ref-type="supplementary-material"}.

10.1371/journal.pone.0105027.t002

###### Clinical, cytological and treatment details of dogs in the study.

![](pone.0105027.t002){#pone-0105027-t002-2}

                                  B cell lymphoma                                                                                                                                                                                                       T cell lymphoma                                                                                                                                                                                                                                                                                    Reactive hyperplasia                                                                                                                                                                                              Mast cell tumor                                                                                                                                                        Healthy control dogs                                          
  ------------------------------ ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Age (months)^1^**             Median (range)                                                                                                                                                                                                         113 (33--171)                                                                                                                                                                                                                                                                                         93 (58--163)                                                                                                                                                                                                   108 (15--156)                                                                                                                                                             138 (84--176)                                                                                                                                                                                                                               55 (19--324)
  **Sex**                               Me                                                                                                                                                                                                                     6                                                                                                                                                                                                                                                                                                    4                                                                                                                                                                                                               1                                                                                                                                                                         0                                                                                                                                                                                                                                           2
                                        Mn                                                                                                                                                                                                                     7                                                                                                                                                                                                                                                                                                    3                                                                                                                                                                                                               6                                                                                                                                                                         0                                                                                                                                                                                                                                          11
                                        Fe                                                                                                                                                                                                                     4                                                                                                                                                                                                                                                                                                    1                                                                                                                                                                                                               1                                                                                                                                                                         1                                                                                                                                                                                                                                           2
                                        Fn                                                                                                                                                                                                                     5                                                                                                                                                                                                                                                                                                    6                                                                                                                                                                                                               6                                                                                                                                                                         5                                                                                                                                                                                                                                          10
  **Breed**                                         Labrador retriever (n = 2); Afghan hound, Australian silky, Bernese mountain dog, Border collie, bullmastiff, cocker spaniel, Doberman, English springer spaniel, flat-coated retriever, German shepherd dog, golden retriever, Jack Russell terrier, Shar pei, Shetland sheepdog, shih tzu, spaniel cross, Staffordshire bull terrier, Tibetan terrier, undefined cross breed, West Highland white terrier (all n = 1)   Boxer (n = 4); Labrador retriever (n = 3); cocker spaniel (n = 2); Border collie, Dogue de Bordeaux, English springer spaniel, golden retriever, Shetland sheepdog (all n = 1)   Fox terrier (n = 2); Labrador retriever (n = 2); Border collie, cocker spaniel, French bulldog, German shepherd dog, Irish terrier, Jack Russell terrier, Labrador cross, Patterdale terrier, Rottweiler, undefined cross breed (all n = 1)   Golden retriever (n = 2); Labrador retriever (n = 2); Rottweiler, undefined cross breed (all n = 1)   Rhodesian ridgeback (n = 3); Border terrier (n = 2); Jack Russell terrier (n = 2); Labrador retriever (n = 2); whippet (n = 2); greyhound, lurcher, standard poodle, boxer cross, Dogue de Bordeaux, Hungarian vizsla, English springer spaniel, Japanese akita, Labrador/English springer spaniel cross, Staffordshire bull terrier (all n = 1); undefined cross breed (n = 4)
  **Body condition^2^**                Under                                                                                                                                                                                                                   4                                                                                                                                                                                                                                                                                                    1                                                                                                                                                                                                               2                                                                                                                                                                         0                                                                                                                                                                                                                                           0
                                      Optimal                                                                                                                                                                                                                 13                                                                                                                                                                                                                                                                                                    9                                                                                                                                                                                                              10                                                                                                                                                                         4                                                                                                                                                                                                                                          24
                                       Over                                                                                                                                                                                                                    5                                                                                                                                                                                                                                                                                                    4                                                                                                                                                                                                               2                                                                                                                                                                         2                                                                                                                                                                                                                                           1
  **WHO stage**                         II                                                                                                                                                                                                                     0                                                                                                                                                                                                                                                                                                    1                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                        III                                                                                                                                                                                                                    9                                                                                                                                                                                                                                                                                                    11                                                                                                                                                                                                             N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                        IV                                                                                                                                                                                                                     7                                                                                                                                                                                                                                                                                                    2                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                         V                                                                                                                                                                                                                     6                                                                                                                                                                                                                                                                                                    0                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
  **Sub-stage**                          a                                                                                                                                                                                                                    11                                                                                                                                                                                                                                                                                                    6                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                         b                                                                                                                                                                                                                    11                                                                                                                                                                                                                                                                                                    8                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
  **Hyper-calcemic?** ^3^               No                                                                                                                                                                                                                    21                                                                                                                                                                                                                                                                                                    9                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                        Yes                                                                                                                                                                                                                    1                                                                                                                                                                                                                                                                                                    4                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
  **Cytological appearance**                                                                                                                                                                                 DLBCL: n = 11; DLBCL or Burkitt-type: n = 2; Undefined: n = 1; Slides not available for review: n = 8                                                                                                                                                                                               PTCL: n = 8; Small cell: n = 1; T zone: n = 1; Undefined: n = 1; Slides not available for review: n = 3                                                                                                                                  Reactive lymphoid hyperplasia confirmed in every case                                                                                                                      Metastatic mast cell tumor confirmed in every case                                                                                                                                                                                                                  N/A
  **Chemotherapy protocol^4^**         CHOP                                                                                                                                                                                                                   14                                                                                                                                                                                                                                                                                                    8                                                                                                                                                                         Various drugs administered, including antimicrobials, NSAIDs and prednisolone                                                                                  Various drugs administered, including vinblastine, prednisolone, lomustine, masitinib and toceranib                                                                                                                                                                                         N/A
                                        COP                                                                                                                                                                                                                    3                                                                                                                                                                                                                                                                                                    1                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                       Other                                                                                                                                                                                                                   3                                                                                                                                                                                                                                                                                                    4                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                       Pred                                                                                                                                                                                                                    1                                                                                                                                                                                                                                                                                                    0                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A
                                       None                                                                                                                                                                                                                    1                                                                                                                                                                                                                                                                                                    1                                                                                                                                                                                                              N/A                                                                                                                                                                       N/A                                                                                                                                                                                                                                         N/A

[Abbreviations]{.ul}: Me, entire male; Mn, neutered male; Fe, entire female; Fn, neutered female; WHO, World Health Organization; N/A, not applicable; DLBCL, diffuse large B cell lymphoma; PTCL, peripheral T cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone protocol; COP, cyclophosphamide, vincristine, prednisolone protocol; Pred, prednisolone alone; NSAIDS, non-steroidal anti-inflammatory drugs.

[Notes]{.ul}: ^1^: Age when presenting signs were first observed. ^2^: Body condition score was assessed by different clinicians on either a 5 or 9 point scale: 'under-conditioned' was defined by a score of 1--2/5 or 1--3/9; 'optimal' was defined by a score of 2.5--3/5 or 4--5/9; while 'over-conditioned' was defined by a score of 3.5--5/5 or 6--9/9. ^3^: Serum or plasma calcium concentration was not measured in one of the T cell lymphoma cases prior to initiation of therapy. ^4^: The initial treatment protocol is listed. 'Other' treatments included cytarabine, L-asparaginase and lomustine (B cell lymphoma) and L-asparaginase, lomustine, prednisolone, masitinib and chlorambucil (T cell lymphoma).

Comparing the BCL, TCL, RH and MCT dogs, there was no significant difference in age (p = 0.51), sex (p = 0.14), neutering status (p = 0.27), bodyweight (p = 0.09) or body condition (p = 0.86) between the groups. The BCL dogs tended to be of higher stage (III 41%, IV 32%, V 27%) than the TCL (II 7%, III 79%, IV 14%; p = 0.02), but there was no difference in sub-stage between the groups (p = 1.00). In common with the prevailing literature, TCL dogs were more commonly hypercalcemic (4/13; 31%) than BCL (1/22, 4.5%; p = 0.05). Among the lymphoma dogs, the cytomorphological characteristics when considered alongside immunophenotype were most commonly consistent with DLBCL (11/22; 50%) and peripheral TCL (8/14, 57%; [Table 2](#pone-0105027-t002){ref-type="table"}, [Figure S1](#pone.0105027.s001){ref-type="supplementary-material"}). The most common chemotherapy protocol in both BCL and TCL dogs was CHOP, comprising cyclophosphamide, doxorubicin, vincristine and prednisolone ([Tables 1](#pone-0105027-t001){ref-type="table"}, [S2](#pone.0105027.s004){ref-type="supplementary-material"} and [S3](#pone.0105027.s005){ref-type="supplementary-material"}).

Treatment of the BCL and TCL dogs with a corticosteroid or any cytotoxic chemotherapeutic drugs within three weeks of sampling was considered a confounding factor, since such drugs may theoretically alter the frequency of peripheral Tregs. Of the BCL cases, 9/21 (43%) dogs had been 'pre-treated' in this way, compared to 5/13 (38%) of the TCL cases. (In each respective BCL and TCL group, one dog received no treatment at all.) Phenotypic characteristics of the pre-treated dogs were no different from those that had not received such drugs prior to sampling (BCL, p\>0.05; TCL, p\>0.05) and pre-treatment had no impact on outcome variables (TTR: BCL, p = 0.58; TCL, p = 0.46; PFS: BCL, p = 0.30; TCL, p = 0.11; OS: BCL, p = 0.28; TCL, p = 0.91). The pre-treated and treatment-naïve groups were therefore considered as a single group in respective BCL and TCL cases. A complete response to chemotherapy was achieved in 17/21 (81%) of the BCL cases and in 8/13 (62%) of the TCL cases. Thus, four of the BCL and five of the TCL dogs were censored from TTR analysis. One dog in each lymphoma group was censored from PFS analysis, while five BCL and two TCL dogs were censored from OS analysis. Comparing the BCL with TCL groups, there was no difference in TTR (BCL: median 20 days *versus* TCL: median 27 days; p = 0.09), PFS (BCL: median 117 days *versus* TCL: median 63 days; p = 0.47) or OS (BCL: median 294 days *versus* TCL: median 151 days; p = 0.21). In the case of the BCL group, older dogs had shorter PFS (median 74 days) than younger dogs (median 174 days; p = 0.006) and dogs treated with CHOP had longer PFS (median 175 days) than those treated with the other protocols (median 45 days; p = 0.01) ([Figure S2](#pone.0105027.s002){ref-type="supplementary-material"}). Rescue therapy, which was unstandardized, was administered to 10 of the BCL dogs and nine of the TCL dogs ([Tables S2](#pone.0105027.s004){ref-type="supplementary-material"} and [S3](#pone.0105027.s005){ref-type="supplementary-material"}). In the case of both the BCL and TCL groups, dogs receiving rescue therapy had longer OS than those not receiving it (BCL: median OS 322 days *versus* 174 days respectively, p = 0.049; TCL: median OS 230 days *versus* 9.5 days respectively, p = 0.008; combined BCL+TCL: 294 days *versus* 102 days respectively, p = 0.013). There was no association with prognosis in either the BCL or the TCL groups for sex, neutering status, body weight, body condition, stage, substage or presence of hypercalcemia (in all cases p\>0.05).

Neoplastic effacement of normal lymphoid tissue impacts FOXP3, Helios and CD8 expression, but the ratio of cytotoxic to regulatory T cells is not decreased in canine B cell lymphoma {#s3b}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The median frequency of FOXP3^+^ cells within the whole population of cells harvested by fine needle aspiration, identified by the 'All' gate, was significantly lower in BCL (1.1% \[0.16%--6.01%\]; n = 22) and TCL (0.86% \[0.01%--5.15%\]; n = 14) cases than in both RH (6.06% \[0.93%--9.50%\]; n = 13) and MCT (5.36% \[2.52%--9.57%\]; n = 4) cases (p = 0.00005; [Figure 2A,B](#pone-0105027-g002){ref-type="fig"}). This was attributed to effacement and thus 'dilution' of normal lymphoid tissue by tumor cells, prompting further examination of FOXP3 expression specifically within the T cell population of BCL, RH and MCT cases. A similarly defined sub-population of non-neoplastic cells could not be delineated in TCLs owing to CD5 expression by the neoplastic cells themselves, precluding such analysis in the TCL cases.

![FOXP3^+^ Treg frequency is no higher in canine B cell lymphoma than control samples.\
The frequency of FOXP3^+^ cells in fine needle aspirates harvested from the lymph nodes of dogs with B cell lymphoma (BCL), T cell lymphoma (TCL), reactive hyperplasia (RH) and mast cell tumors (MCT) is shown, expressed as a proportion of all cells (A, B, showing the effect of neoplastic effacement of normal lymphoid tissue; p = 0.00005), gated CD5^+^ cells (C, showing the resident T cells; p = 0.41), or sequentially gated CD5^+^ and then CD4^+^ T cells (D, showing specifically the resident CD4^+^ T cells; p = 0.74). Representative dot plots are shown for each of the groups, followed by box-and-whisker plots summarising the data. In each of the dot plots, the respective isotype control stain is shown above the specific stain. In this and subsequent figures, red symbols correspond to data from dogs 'pre-treated' with corticosteroids or any chemotherapeutic drug within three weeks of sampling. In the case of RH cases, square symbols (□) represent data from dogs with dermatitis; diamonds (◊) represent data from dogs with distant neoplasia; triangles (Δ) represent data from dogs with immune-mediated disease; and inverted triangles (▾) represent data from dogs with systemic infection. The expression of FOXP3 by PBMCs (E; p = 0.21) or by the CD5^+^ (F; p = 0.53) or specific CD5^+^CD4^+^ (G; p = 0.15) T cells within PBMCs similarly showed no differences between groups.](pone.0105027.g002){#pone-0105027-g002}

A variable pattern of FOXP3 expression was observed in BCL lymph node aspirates, but there was no overall difference between groups when FOXP3 was examined in either the CD5^+^ population (BCL: 8.56% \[0.77%--18.1%\], n = 22; RH: 10.8% \[0.37%--18.1%\], n = 14; MCT: 9.43% \[0.96%--11.7%\], n = 4; p = 0.41) or the specific CD4^+^CD5^+^ T cells (BCL: 6.21% \[0.57%--17.1%\], n = 22; RH: 6.79% \[0.38%--13.4%\], n = 14; MCT: 9.51% \[5.64%--10.6%\], n = 4; p = 0.74) within the lymph nodes ([Figure 2C,D](#pone-0105027-g002){ref-type="fig"}). Furthermore, there was no overall difference in expression of FOXP3 by PBMCs between groups (BCL: 0.57% \[0.05%--5.07%\], n = 10; TCL: 0.31% \[0.05%--1.96%\], n = 9; RH: 0.67% \[0.07%--6.67%\], n = 5; MCT: 12.04%, n = 1; p = 0.21) ([Figure 2E](#pone-0105027-g002){ref-type="fig"}). A similar lack of difference in FOXP3 expression between groups was also apparent when its expression within the CD5^+^ (BCL: 2.03% \[0.25%--9.91%\], n = 11; TCL: 4.31% \[0.18%--6.48%\], n = 8; RH: 4.74% \[2.43%--10.30%\], n = 6; MCT: 5.9%, n = 1; p = 0.53) or specific CD4^+^CD5^+^ T cell fractions of PBMCs was examined (BCL: 5.29% \[0.21%--13.85%\], n = 10; TCL: 5.41% \[0.258%--16.02%\], n = 9; RH: 8.36% \[5.23%--10.96%\], n = 6; MCT: 16.13%, n = 1; p = 0.15) ([Figure 2F,G](#pone-0105027-g002){ref-type="fig"}).

The median frequency of expression of Helios within the whole population of aspirated cells was markedly higher in TCL cases (33.1% \[0.6%--94.0%\]; n = 13) than in the other three groups of dogs (BCL: 3.0% \[0.1%--52.3%\], n = 22; RH: 6.65% \[0.60%--8.90%\], n = 12; MCT: 6.38% \[0.50%--9.13%\], n = 5; p = 0.00003), compatible with neoplastic T cell Helios expression rather than localization of Helios to the thymic Tregs alone ([Figure 3A,B](#pone-0105027-g003){ref-type="fig"}).

![Canine T cell lymphoma is associated with high-frequency Helios expression.\
Helios expression by cells harvested by fine needle aspiration from the lymph nodes of dogs with B cell lymphoma (BCL), T cell lymphoma (TCL), reactive hyperplasia (RH) and mast cell tumors (MCT) was examined as a marker for thymic Tregs, but the unexpectedly high frequency of Helios^+^ events in a few B cell and several T cell lymphoma cases suggested neoplastic expression of this marker. Median frequency of Helios expression was significantly different between the groups (p = 0.00003). Representative dot plots for BCL and TCL cases, with their respective isotype control stains, is shown (A), followed by box-and-whisker plots summarising the data (B). (For key to symbols, refer to [Figure 2](#pone-0105027-g002){ref-type="fig"}).](pone.0105027.g003){#pone-0105027-g003}

Expression of Helios was therefore of limited use in the identification of thymic Tregs in TCL.

The median frequency of CD8^+^ cells within the whole population of harvested cells was significantly lower in the BCL cases (2.68% \[0.89%--10.7%\]; n = 20) than in RH cases (11.1% \[1.17%--17.1%\], n = 20; p = 0.0005), again attributed to effacement of the normal lymphoid population by neoplastic cells ([Figure 4A,B](#pone-0105027-g004){ref-type="fig"}). In the case of this marker, median expression was also low in the MCT cases (2.24% \[0.82%--6.9%\]; n = 4). The median expression of CD8 specifically by T cells was also lower in the neoplastic groups than in the RH group (BCL: 11.3% \[0.57%--30.4%\], n = 20; MCT: 7.06% \[5.35%--9.76%\], n = 3; RH: 18.4% \[0.6%--37.1%\], n = 11; p = 0.04) ([Figure 4C](#pone-0105027-g004){ref-type="fig"}). Rationalizing that the balance of cytotoxic to regulatory T cells may be perturbed in BCL, we then examined the ratio of CD8^+^ to FOXP3^+^ T cells within the whole population of harvested cells. Rather than being lower in BCL cases, the median CD8^+^:FOXP3^+^ ratio showed a trend towards being higher in this group of dogs when compared to RH (or MCT) cases (BCL: 2.09 \[0--27.7\], n = 22; RH: 1.63 \[0--5.89\], n = 13; MCT: 0.35 \[0--1.07\]; n = 4; p = 0.06), which became significant when thymic Tregs were specifically examined by means of co-expression of FOXP3 and Helios within the overall population (BCL: 15.6 \[2.11--36.1\], n = 11; RH: 4.26 \[0--12.0\], n = 13; p = 0.04) ([Figure 4D,E](#pone-0105027-g004){ref-type="fig"}).

![Canine B cell lymphoma shows no deficit of cytotoxic T cells relative to thymic Tregs.\
When expressed as a proportion of all cells aspirated from the lymph node, the frequency of CD8^+^ T cells (A,B) was decreased in BCL (and MCT), again attributed to neoplastic effacement (p = 0.0005). The frequency of CD8^+^ cells within the CD5^+^ T cell population also showed differences between groups (C; p = 0.04). The ratio of CD8^+^:FOXP3^+^ cells (D) was not significantly different between groups (p = 0.06), though dogs with BCL showed the six highest ratios of the cohort, and a trend for higher values in the BCL group was observed. Indeed, the ratio of CD8^+^:FOXP3^+^Helios^+^ cells (E) was higher in the BCL than RH cases (p = 0.04); only two data points for the MCT (3.48; 3.95) were available for this variable and were not therefore represented. Representative dot plots for all the groups are shown alongside their respective isotype controls, followed by box-and-whisker plots summarising the data. (For key to symbols, refer to [Figure 2](#pone-0105027-g002){ref-type="fig"}).](pone.0105027.g004){#pone-0105027-g004}

FOXP3, Helios and MHC class II expression all have prognostic significance in canine B cell lymphoma {#s3c}
----------------------------------------------------------------------------------------------------

The impact of FOXP3, Helios and MHC class II expression on BCL prognosis was then interrogated using both univariable and multivariable analysis. FOXP3 expression was a negative prognostic factor in the context of OS and PFS. Patients with total FOXP3 expression less than or equal to the median value (1.23%) survived longer than those with expression above the median value (≤1.23%, median OS = 322 days, \>1.23%, median OS = 169 days; median ratio 0.52; p = 0.018) ([Figure 5A](#pone-0105027-g005){ref-type="fig"}). A similar phenomenon was observed for PFS: patients with lower FOXP3 expression in the CD5^+^CD4^+^ population had a longer PFS than those with higher FOXP3 expression (≤10.2%, median PFS = 211 days, \>10.2%, median PFS = 61 days; median ratio 0.29; p = 0.012) ([Figure 5B](#pone-0105027-g005){ref-type="fig"}). The proportional expression of Helios was also a negative prognostic factor, as patients with expression lower than the median value had longer PFS (≤3.00%, median PFS = 175 days, \>3.00%, median PFS = 62 days; median ratio 0.35; p = 0.014) ([Figure 5C](#pone-0105027-g005){ref-type="fig"}). The intensity of MHC class II expression by the lymphoma cells, expressed as the ratio of geometric mean fluorescence intensity of MHC II^+^:MHC II^−^ cells within the CD5^−^ subset of the 'All' gate, was also of prognostic significance ([Figure 5D](#pone-0105027-g005){ref-type="fig"}): TTR was longer in those cases with expression ratios less than or equal to the median value (≤4.40, median 22 days, \>4.40, median 10 days; p = 0.017).

![Expression of T cell FOXP3 and Helios, and tumor cell MHC class II, all impact prognosis in dogs with B cell lymphoma.\
The frequency of FOXP3^+^ cells within the 'All' gate (A), or within a cascaded All→CD5^+^→CD4^+^ gate (B), influenced survival times. Overall survival times were shorter in those dogs with frequencies of FOXP3^+^ T cells higher than the median value (A: p = 0.02); a similar pattern in progression-free survival (PFS) was observed (B: p = 0.01). The frequency of Helios^+^ cells within the 'All' gate also influenced PFS (C: p = 0.01). The intensity of MHC class II expression by the lymphoma cells, expressed as the ratio of geometric mean fluorescence intensity of MHC II^+^:MHC II^−^ cells within the CD5^−^ subset of the 'All' gate, was also of prognostic significance: time to remission was longer in those cases with less MHC class II expression per cell (D: p = 0.02).](pone.0105027.g005){#pone-0105027-g005}

Multivariable analysis yielded two independent factors impacting PFS, age and frequency of FOXP3 expression by lymph node CD5^+^CD4^+^ T cells, and two independent factors impacting OS, the administration of rescue therapy and the frequency of FOXP3 expression within the total harvested population ([Table 3](#pone-0105027-t003){ref-type="table"}). In the case of OS analysis, a similar proportion of dogs in the FOXP3^low^ (≤1.23%: 6/11) and FOXP3^high^ (\>1.23%: 4/10) group had received rescue therapy (p = 0.67). Univariable analysis identified only a single factor impacting TTR (MHC class II expression), obviating the need for multivariable analysis for this outcome variable.

10.1371/journal.pone.0105027.t003

###### FOXP3, MHC class II, age at presentation and rescue therapy are independent prognostic factors in canine B cell lymphoma.

![](pone.0105027.t003){#pone-0105027-t003-3}

  Outcome metric            Variable            Median ratio   Hazard ratio (95% CI)   p value
  ---------------- --------------------------- -------------- ----------------------- ---------
  TTR                     MHC class II              0.45         2.44 (1.36--4.35)      0.003
  PFS                          Age                  0.43         1.02 (1.01--1.04)      0.007
                    FOXP3^+^ (% CD5^+^CD4^+^)       0.29         1.10 (1.02--1.18)      0.01
  OS                     Rescue therapy             0.54         0.29 (0.09--0.90)      0.03
                          FOXP3^+^ (%)              0.52         1.61 (1.11--2.32)      0.01

[Abbreviations]{.ul}: TTR, time to remission; PFS, progression-free survival; OS, overall survival; CI, confidence interval; FOXP3^+^ (% CD5^+^CD4^+^), frequency of FOXP3^+^ cells within the sequential CD5^+^ and CD4^+^ gates; FOXP3^+^ (%), frequency of FOXP3^+^ cells within the total harvested population; median ratio =  ratio of median remission or survival time (TTR/PFS/OS) of the sub-group of dogs with a value of the variable greater than the median of the group to that of the sub-group of dogs with a value of the variable less than or equal to the median of the group.

Discussion {#s4}
==========

To the authors\' knowledge, this study represents the first attempt to define the prognostic impact of Tregs in a well-characterized cohort of canine cases of multicentric BCL. Despite the relatively small size of the cohort and heterogeneity of treatment protocols, the expression of FOXP3 emerged as an independent prognostic factor, alongside the expression of MHC class II, age at presentation and the administration of rescue therapy. This observation raises the intriguing possibility that the dog, in common with other species, harbors thymic Tregs within the neoplastic microenvironment of BCL, which are likely to interact with the neoplastic B cells, stromal cells, and other regulatory populations such as tolerogenic dendritic cells, tumor-associated macrophages, myeloid-derived suppressor cells and γδ T cells.

Control dogs included those with TCL, non-neoplastic lymphadenomegaly (RH) and metastatic MCTs, the latter as an example of an alternative round cell tumor. In common with previous literature, boxers appeared to be over-represented in the TCL group (4/14, 29%) [@pone.0105027-Modiano1]--[@pone.0105027-Pastor1] and dogs with TCL were more commonly hypercalcemic than those with BCL [@pone.0105027-Greenlee1], [@pone.0105027-FournelFleury1]. Cytological reviews were possible in 14 of 22 BCL and 11 of 14 TCL cases, suggesting a predominance of DLBCL and peripheral TCL. This observation accords with both previous veterinary literature, in which these cytological classifications were the most commonly recognized among multicentric BCL and TCL cases [@pone.0105027-Ponce1], [@pone.0105027-FournelFleury2], [@pone.0105027-Ponce2], and reviews of human NHL [@pone.0105027-Shankland1], [@pone.0105027-Mey1]. The similar cytological appearance of the most common types of canine and human BCL adds weight to the notion that the canine disease could model NHL [@pone.0105027-Marconato1]. However, although FNAs are still the cornerstone of lymphoma diagnosis in canine patients and serve an important triaging role in people with lymphadenomegaly by virtue of their ease of procurement [@pone.0105027-Das1]--[@pone.0105027-Vigliar1], solid tissue biopsies are considered the gold standard for diagnosis of human patients, allowing a detailed tissue architectural classification of lymphoma subtypes [@pone.0105027-Guerard1], [@pone.0105027-Shankland1]. Recent years have seen an increasing recognition of the diagnostic and prognostic value of histopathological subtypes of lymphoma in dogs [@pone.0105027-Ponce2], [@pone.0105027-Aresu1], [@pone.0105027-Valli1], which generally show remarkable similarity to those of human patients [@pone.0105027-Ponce1], [@pone.0105027-FournelFleury2], [@pone.0105027-Valli2].

Most of the dogs in this study were treated with a CHOP protocol, considered to be the standard of care in the treatment of canine lymphoma [@pone.0105027-Marconato2], [@pone.0105027-Chun1]; anti-canine CD20 mAbs similar to rituximab are not currently available, precluding R-CHOP. A proportion of the dogs had received at least one of the drugs on at least one occasion within three weeks of sampling for this study, prompting concern that such 'pre-treatment' might influence their immune cell profile. In particular, we were concerned that prior use of corticosteroids or cyclophosphamide would alter Treg frequencies, given the known impact of these drugs on peripheral T cells in rodents [@pone.0105027-Liu1]--[@pone.0105027-Mao1], humans [@pone.0105027-Zhao1]--[@pone.0105027-Zen1] and dogs [@pone.0105027-Burton1]. However, neither the cellular phenotype nor the prognosis of the pre-treated dogs was significantly different from that of the treatment-naïve patients, presumably because such drugs were administered on a limited number of occasions prior to sampling and would thus have had only minimal opportunity to impact the immune system. Recent studies of human patients receiving short-term glucocorticoid therapy have similarly shown no change in the frequency of peripheral Tregs [@pone.0105027-Moniuszko1], [@pone.0105027-Sbiera1]. In view of the lack of impact of pre-treatment on these variables, all dogs of the respective B and T cell groups were considered together in our final analysis.

The impact of a number of clinical and immunophenotypic variables on TTR, PFS and OS of dogs with multicentric lymphoma was examined in the current study, including B or T cell phenotype, age, sex, neutering status, bodyweight, body condition, stage, substage, presence of hypercalcemia, treatment protocol (CHOP *versus* 'Other') and the administration of rescue therapy. Other than the predictable impact of rescue therapy on OS, multivariable analysis revealed that age was the only factor with an independent impact on prognosis, younger dogs enjoying longer PFS. This has been a finding in other canine studies [@pone.0105027-Valli1] and also reflects the situation in human NHL, for which the prognosis is worse in elderly patients [@pone.0105027-Armand1], [@pone.0105027-XX1]. The pathophysiological basis of this observation remains unclear, but is thought to reflect the generally poorer cellular repair mechanisms, progressive immunosenescence, propensity for chemoresistant molecular subtypes of DLBCL, and increased spectrum of comorbidities that occur with advancing age [@pone.0105027-Fields1].

Prognostic factors in other canine studies of multicentric lymphoma have included sex [@pone.0105027-MacEwen1], [@pone.0105027-Keller1], B or T immunophenotype [@pone.0105027-Greenlee1], [@pone.0105027-Dobson1]--[@pone.0105027-Ruslander1], stage [@pone.0105027-Teske1], [@pone.0105027-Jagielski1]--[@pone.0105027-Wiedemann1], substage [@pone.0105027-Keller1], [@pone.0105027-Jagielski1], serum calcium concentration [@pone.0105027-Weller1], packed cell volume [@pone.0105027-Miller1], monocyte concentration [@pone.0105027-Perry1], prior administration of corticosteroids [@pone.0105027-Price1], [@pone.0105027-Khanna1], treatment protocol [@pone.0105027-Valli1], [@pone.0105027-Carter1], coagulation profile [@pone.0105027-Kol1], presence of minimal residual disease after treatment [@pone.0105027-Sato1], and cytomorphological and histopathological characteristics [@pone.0105027-Ponce2], [@pone.0105027-Aresu1], [@pone.0105027-Valli1], [@pone.0105027-Teske1]. However, in common with our own observations, different studies have yielded different conclusions and have not all been able to demonstrate a prognostic impact of every one of the examined variables: factors such as the number and clinical heterogeneity of recruited patients and the nature of the specific end points examined influence the results of such outcome analyses [@pone.0105027-Webster1]. More recent studies have stratified canine BCL patients by gene profiling, demonstrating that in common with human DLBCL two subtypes with different survival times -- the germinal center B cell-like and the activated B cell-like -- can be distinguished, the latter associated with a poorer prognosis [@pone.0105027-Richards1], [@pone.0105027-Su1]. While the individual genes were different between the species, the general pathways characterizing these subtypes were strikingly similar [@pone.0105027-Richards1].

We used a cross-reactive mAb against murine Foxp3, validated for use in dogs [@pone.0105027-Pinheiro1], [@pone.0105027-Mizuno1], to identify Tregs in this study. While a large number of markers for Tregs have been proposed, FOXP3 remains the single most widely applied phenotypic credential of regulatory activity in cancer and other studies [@pone.0105027-Flammiger1]--[@pone.0105027-Kryczek1], despite being transiently expressed in activated human and canine conventional T cells lacking regulatory function [@pone.0105027-Pinheiro1], [@pone.0105027-Wang1]. Comparisons of respective FOXP3^+^ and CD8^+^ cells between the study groups yielded the initially surprising observation that dogs with lymphoma had lower frequencies of these cells than those with RH and MCTs. While FNAs of lymph nodes only ever approximate the cellular content of the node, a consistent aspiration technique was applied between patients and we could not attribute these differences to trivial anomalies in the cellular harvest of lymphomatous lymph nodes, which readily exfoliate cells. Rather, we attributed this observation to cellular effacement of the normal lymphoid tissue by neoplastic B or T cells.

The expression pattern of Helios was also unanticipated. Applied as a marker of thymic Tregs in our study [@pone.0105027-Thornton1], the high frequency of its expression in a number of TCL and two BCL cases suggested that neoplastic lymphocytes may also express this transcription factor, especially those of T cell origin. This intriguing observation accords with similar findings in human TCL, in which over-expression of non-DNA-binding, dominant negative isoforms of Helios is thought to be involved in disease progression [@pone.0105027-Fujii1]. Indeed, transgenic expression of short Helios isoforms in mice promotes the development of TCL [@pone.0105027-Zhang1], while ectopic expression of full-length Helios in B cells promotes BCL [@pone.0105027-Dovat1], suggesting a potential pathogenic role in both immunophenotypes. It is tempting to speculate that deregulated expression of Helios may also be implicated in a minority of BCLs and some TCLs in dogs. Insufficient data were available to allow survival analysis of the Helios^high^ group, but this could be a rewarding avenue for future research; furthermore, immunocytochemical staining could be employed to confirm expression of Helios by the malignant T cells. In the light of these observations, Helios was used as a surrogate marker for thymic Tregs only in the BCL dogs.

Review of the initial flow cytometric data prompted us to adopt a cascaded gating approach in subsequent analysis of the BCL cases, in which sequential CD5^+^ and CD4^+^ gates were applied to identify the resident T cells. By 'normalizing' the data in this manner, we endeavored to remove the dilutional influence of the neoplastic B cells. We found no significant difference in the frequency of FOXP3^+^ cells between the BCL and two control groups, when expressed either as a proportion of CD5^+^ or of CD5^+^CD4^+^ T cells. This observation contrasts with both a comparison of the cellular phenotype of lymph nodes in human patients with Hodgkin lymphoma and RH [@pone.0105027-Hudnall1], and a recent study by Mitchell *et al*, who examined the cytotoxic T cell response in dogs with multicentric BCL treated with doxorubicin: the mean initial frequency of Tregs was approximately four-fold higher in Mitchell\'s study than in ours [@pone.0105027-Mitchell1]. While this disparity is difficult to explain given the commonality of the species and disease, there were some notable differences between the studies. Thus, Mitchell *et al* harvested excisional biopsies, which represent a more accurate sampling technique than FNAs, but recruited only five dogs with BCL in total. We speculate that the five dogs included in their study represented a Treg^high^ phenotype, reminiscent of the highest-expressing patients in our own work, but that the pattern of expression is generally more heterogeneous among all dogs with BCL. Furthermore, for ethical and legal reasons we were unable to sample the lymph nodes of healthy animals; our comparisons were thus restricted to dogs with non-neoplastic lymphadenomegaly and infiltration of the lymph nodes by another round cell tumor, both of which could have harbored higher frequencies of Tregs than healthy dogs. Indeed, this notion of non-malignant expansion of Tregs reconciles with the known activation of these cells in the context of inflammatory microenvironments [@pone.0105027-Chaudhry1].

Among the populations of cytotoxic cells within a tumor, CD8^+^ T cells play a prominent role in the elimination of neoplastic cells [@pone.0105027-Lanca1]. Conventional wisdom places them on the other side of a balancing act with Tregs and additional regulatory cells in solid cancers [@pone.0105027-LakshmiNarendra1]. We thus explored the possibility of a perturbation of the relative frequencies of CD8^+^ and FOXP3^+^ T cells in BCL, but found no evidence of a deficit of the former when compared to the control groups. Rather, the ratio of CD8^+^ to regulatory T cells tended to be higher in the lymph nodes of the BCL than RH dogs, especially when thymic Tregs were identified by means of Helios expression. While Helios has been criticized as a marker for thymic Tregs [@pone.0105027-Akimova1], it is still generally regarded to be a valid surrogate for this population of regulatory cells [@pone.0105027-Onoe1]. Future studies could also examine the cross-reactivity of available mAbs against neuropilin-1, considered by some to be a superior marker [@pone.0105027-Lin1] and implicated in Treg-mediated suppression within certain cancer microenvironments [@pone.0105027-Hansen1]. Taken together, these data provided no support for a gross numerical deficit of CD8^+^ T cells in canine BCL, but further work will be required to explore possible functional deficits of these critical cells.

Despite the lack of a significant difference in overall T cell FOXP3 expression between the BCL and control groups, FOXP3 nevertheless emerged as an independent negative prognostic factor in this study. This apparent paradox was likely to reflect the very different microenvironments of B cell neoplasia and lymphoid hyperplasia and the role of Tregs within them: in the context of cancer, Tregs have traditionally been viewed as having a pathogenic influence [@pone.0105027-Gallimore1], [@pone.0105027-Oleinika1], [@pone.0105027-Lindau1], co-opted by the cancer to help thwart anti-neoplastic immune responses [@pone.0105027-Malchow1], while in the context of RH, Tregs are likely to serve a beneficial role by limiting over-exuberant inflammatory responses and collateral tissue damage, adapting their suppressive program to the prevailing milieu [@pone.0105027-Chaudhry1]. While our data reconciled with this view of Tregs as being 'bad' in the context of canine BCL, aligning with a plethora of studies of solid tissue cancers in humans and other species [@pone.0105027-Gallimore1], [@pone.0105027-Oleinika1], [@pone.0105027-Lindau1] and some studies of human NHL [@pone.0105027-Marshall1]--[@pone.0105027-Schreck1], it was at odds with a proportion of studies of human lymphoma that have suggested the exact opposite -- that Tregs are actually part of the anti-neoplastic defenses [@pone.0105027-Alvaro1]--[@pone.0105027-Dehghani1], presumably because they are able to draw on their armamentarium of suppressive mechanisms to neutralize or kill neoplastic T and B cells, as well as a host of innate immune cells subverted by the lymphoma. The bewildering complexity of the microenvironment in both solid tissue and hemolymphatic tumors is only now beginning to be elucidated [@pone.0105027-Schiavoni1]--[@pone.0105027-Fridman1] and we speculate that Tregs may have divergent and dynamic roles in this context that are predicated on both micro-anatomical and temporal factors. Whether FOXP3^+^ Tregs play a negative prognostic role in all canine BCL subtypes remains to be determined, but they appeared to be deleterious in the context of the cohort of dogs we examined. High Helios and low MHC II expression were also of prognostic significance in this study. We suggest that the Helios result reflects its predominant co-localization with FOXP3 in thymic Tregs, while the MHC II result reconciles with studies of both human [@pone.0105027-Rimsza1]--[@pone.0105027-Veelken1] and canine [@pone.0105027-Rao1] BCL patients, in which low-level expression of this molecule is thought to compromise the activation of T cell responses against the neoplastic B cells and thus shorten survival. Interestingly, the current study revealed an impact of MHC II expression on TTR alone, but differences in patients and study design were likely to account for this discrepancy from existing publications.

In common with all clinical research of an exploratory nature, this study suffered a number of limitations. Staging was not complete in every case and our end-point variables (TTR, PFS and OS) were defined by owners\' and attending veterinarians\' observations of clinical signs and lymph node size. While diligent follow-up of cases was undertaken, the pragmatic nature of clinical veterinary practice meant that these values were likely to be best estimates only. Furthermore, the cohort of BCL patients examined was uncontrolled and relatively small, incorporating a number of different treatment regimens. We chose not to censor dogs that had received rescue therapy, instead incorporating them in the analysis of OS to maximize power. Nevertheless, despite the heterogeneity of the cohort, we were able to demonstrate that frequency of FOXP3 expression was an independent prognostic factor. Future studies of carefully stratified canine lymphoma patients treated with the same chemotherapy protocol are planned to confirm the results of the current work, which must be considered preliminary until they are prospectively validated in this manner.

In summary, we have presented evidence suggesting that FOXP3^+^ Tregs have a negative prognostic impact in canine multicentric BCL. We suggest that dogs with BCL, in common with human NHL patients, harbor a spectrum of interacting regulatory cells within the neoplastic lymph nodes, including thymic Tregs. We present further evidence of similarities between canine BCL and human NHL, thus helping to vindicate this large animal model of lymphoid cancer. There is an increasing need to find new ways of modulating the immune system as an integral part of multimodal veterinary cancer therapy. Regulatory T cells are an obvious candidate in such therapeutic endeavors, since this work suggests that they play a decisive role in the pathogenesis of canine BCL.

Supporting Information {#s5}
======================

###### 

**Cytological characteristics of representative B cell lymphoma, T cell lymphoma, reactive hyperplasia and mast cell tumor cases.** Smears of fine needle aspirates were stained with modified Wright\'s stain and examined by a board-certified clinical pathologist in each case to reach a cytological diagnosis. A representative image of each group is presented (100x oil immersion lens; bar = 10 µm). (A) Diffuse large B cell lymphoma (DLBCL), characterized by a dominance of medium-to-large lymphocytes with immature chromatin and prominent nucleoli. (B) Peripheral T cell lymphoma (PTCL), characterized by a dominance of medium-to-large lymphocytes with eccentric and occasionally indented nuclei, smooth chromatin and multiple nucleoli. (C) Reactive hyperplasia (RH), characterized by a mixed population of lymphocytes with predominance of small lymphocytes, and increased numbers of medium-to-large lymphocytes, plasma cells and Mott cells. (D) Draining lymph node of a mast cell tumor (MCT), characterized by numerous moderately-to-well granulated mast cells, occasional eosinophils and a mixed lymphocyte population, consistent with a metastatic mast cell tumor.

(TIF)

###### 

Click here for additional data file.

###### 

**Younger dogs, those treated with CHOP and those 'rescued' show longer survival in B cell lymphoma.** (A) Dogs with B cell lymphoma that were less than or equal to the median age of the group (112 months) had longer progression-free survival (PFS: median 174 *vs* 74 days; median ratio = 0.43, p = 0.006) but not overall survival (OS, p = 0.11; data not shown); time to remission (TTR) was also no different between younger and older dogs (p = 0.57; data not shown). The significance of age on PFS remained in the multivariable regression model, demonstrating that it was an independent prognostic factor in this cohort of dogs. (B) CHOP chemotherapy was associated with longer PFS than the other treatments in the BCL group (CHOP, median 175 days; Other \[including COP (n = 3), cytarabine, L-asparaginase, lomustine (n = 3) and prednisolone alone (n = 1)\], median 45 days; p = 0.01). However, when interrogated in multivariable analysis, the variable 'protocol' no longer remained significant after accounting for age, reflecting the younger mean age of dogs treated with CHOP than 'Other' protocols (93 *versus* 123 months; p = 0.05). (C) Dogs receiving rescue therapy had longer OS (median 322 days) than those not receiving rescue therapy (174 days, median ratio 0.54; p = 0.049).

(TIF)

###### 

Click here for additional data file.

###### 

**Cytomorphological criteria for the assessment of lymphoma cases.**

(DOC)

###### 

Click here for additional data file.

###### 

**Signalment, therapy and immunophenotype of B cell lymphoma dogs.** [Abbreviations]{.ul}: mo, months; m, male; f, female; n, neutered; e, entire; ND, not determined; chemotherapy agents: CHOP, protocol in which cyclophosphamide (C), doxorubicin (H), vincristine (O) and prednisolone (P) are administered; COP, protocol in which cyclophosphamide (C), vincristine (O) and prednisolone (P) are administered; L, lomustine; Cy, cytosine arabinoside; Ap, L-asparaginase; Chl, chlorambucil; VCAA, protocol in which vincristine (V), cyclophosphamide (C), L-asparaginase (A) and doxorubicin (A) are administered; LMP, protocol in which chlorambucil (L), methotrexate (M) and prednisolone (P) are administered; DMAC, protocol in which dexamethasone (D), melphelan (M), actinomycin-D (A) and cytosine arabinoside (C) are administered; Ma, masitinib; Vb, vinblastine; Pr, procarbazine; -, no rescue therapy administered (Rescue therapy) or remission not achieved (TTR); +, no progression (PFS) or alive at conclusion of study (OS) and therefore censored from survival analysis. [Notes]{.ul}: The immunophenotype lists the per cent positive staining for the listed antigen; ^1^: these cases were classified as B cell lymphomas with aberrant CD5 expression.
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Click here for additional data file.

###### 

**Signalment, therapy and immunophenotype of T cell lymphoma dogs.** [Abbreviations]{.ul}: mo, months; m, male; f, female; n, neutered; e, entire; ND, not determined; chemotherapy agents: see [Table S2](#pone.0105027.s004){ref-type="supplementary-material"} and Dex, dexamethasone; -, no rescue therapy administered (Rescue therapy) or remission not achieved (TTR); +, no progression (PFS) or alive at conclusion of study (OS) and therefore censored from survival analysis. [Notes]{.ul}: The immunophenotype lists the per cent positive staining for the listed antigen.

(DOC)
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Click here for additional data file.

###### 

**Disease subtype and signalment of reactive hyperplasia dogs.** [Abbreviations]{.ul}: mo, months; m, male; f, female; n, neutered; e, entire.

(DOC)
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Click here for additional data file.

###### 

**Signalment of mast cell tumor dogs.** [Abbreviations]{.ul}: mo, months; f, female; n, neutered; e, entire.

(DOC)

###### 

Click here for additional data file.
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